tocilizumab sold brand name actemra among others immunosuppressive drug used treatment rheumatoid arthritis systemic juvenile idiopathic arthritis severe form arthritis children humanized monoclonal antibody receptor interleukin cytokine plays important role immune response implicated pathogenesis many diseases autoimmune diseases multiple myeloma prostate cancer tocilizumab jointly developed osaka university chugai licensed hoffmannla tocilizumab approved medical use united states january united states tocilizumab indicated treatment rheumatoid arthritis giant cell arteritis systemic sclerosisassociated interstitial lung disease polyarticular juvenile idiopathic arthritis systemic juvenile idiopathic arthritis cytokine release syndrome european union tocilizumab indicated treatment rheumatoid arthritis juvenile idiopathic arthritis juvenile idiopathic polyarthritis giant cell arteritis cytokine release syndrome tocilizumab used treatment moderate severe rheumatoid arthritis applied combination methotrexate drugs like diseasemodifying antirheumatic drugs dmards tnf alpha blockers proven ineffective tolerated used monotherapy patients tolerate drug slows progression disease improve physical function treatment systemic juvenile idiopathic arthritis sjia similar rheumatoid arthritis treatment tocilizumab combined methotrexate unless latter tolerated general safety effectiveness established children two years us food drug administration fda approved tocilizumab treatment active systemic juvenile idiopathic japan tocilizumab also approved treatment castlemans rare benign tumor b cells may fda approved tocilizumab giant cell temporal august fda approved tocilizumab cytokine release syndrome side effect cart cell june us food drug administration fda issued emergency use authorization eua tocilizumab treatment hospitalized people aged two years age older receiving systemic corticosteroids require supplemental oxygen noninvasive invasive mechanical ventilation extracorporeal membrane oxygenation fda approved tocilizumab indications december common adverse effects observed clinical trials upper respiratory tract infections patients nasopharyngitis common cold headache high blood pressure least enzyme alanine transaminase also elevated least patients cases without symptoms elevated total cholesterol levels among less common side effects dizziness various infections well reactions skin mucosae like mild rashes gastritis mouth ulcer rare severe reactions gastrointestinal perforations six months anaphylaxis certain interactions drugs blood plasma levels simvastatin reduced single dose tocilizumab known whether clinically relevant possible mechanism elevated levels patients rheumatoid arthritis suppress biosynthesis various cytochrome enzymes notably tocilizumab lowers thus normalises cytochrome levels increasing metabolization simvastatin possibly cytochrome metabolised besides functions interleukin involved development immunological inflammatory reactions autoimmune diseases like rheumatoid arthritis associated abnormally high levels tocilizumab binds soluble well membrane bound receptors hindering exerting proinflammatory noted membrane bound form soluble form receptor may different effects pathogenesis rheumatoid arthritis soluble form implicated disease interleukin receptor discovered cloned osaka university japan tadamitsu kishimoto chugai pharmaceuticals began clinical development tocilizumab treatment rheumatoid arthritis clinical studies castlemans disease systemic juvenile idiopathic arthritis started respectively roche codeveloped drug due license agreement data presented showed effectiveness tocilizumab combination therapy methotrexate rheumatoid arthritis studies effective generally well tolerated administered either monotherapy combination conventional dmards adult patients moderate severe rheumatoid june tocilizumab approved japan castlemans january drug approved european medicines agency ema roactemra treatment rheumatoid arthritis mentioned restrictions january approved us fda actemra tocilizumab approved australias therapeutic goods administration may listed pharmaceutical benefits scheme august new zealand tocilizumab approved distribution july pharmac approved subsidising special authority restrictions july systemic juvenile idiopathic july rheumatoid fda approved tocilizumab treatment systemic juvenile idiopathic arthritis children two years age april ema followed august year tocilizumab marketed chugai countries especially japan asian countries jointly chugai roche roches holding company others example great britain france tocilizumab approved medical use united states january tocilizumab approved treatment european union december united states december september indian pharmaceutical firm hetero obtained emergency use approval countrys health authority drugs controller general india dcgi produce generic version tocilizumab treat december tocilizumab granted provisional approval australian regulator therapeutic goods administration treatment tocilizumab granted emergency use authorization eua treatment united states june approved treatment european union december united states december tocilizumab studied pulmonary arterial hypertension tocilizumab currently evaluation multicenter clinical trial allin prevention acute cellular rejection status post heart transplant good evidence tocilizumab help reduce need mechanical ventilation people hospital evidence help prevent secondary metaanalysis randomized controlled trials found tocilizumab show significant benefits survival could play role preventing progression intensive care mechanical early case reports suggest tocilizumab might effective otherwise refractory neuromyelitis optica nmo devics two small studies found tocilizumab beneficial endocrine ophthalmopathy graves orbitopathy refractory corticosteroid immune activation dostarlimab ibalizumab httpsenwikipediaorgwikitocilizumab